| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Shark Cartilage is an Ineffective Cancer Treatment, Study Concludes ZION, Ill., May 23, 1997 -- Shark cartilage is not an effective treatment for advanced-stage cancer in adults, according to the results of a study presented during the 33rd Annual Meeting of the American Society of Clinical Oncology in Denver. The study was sponsored by Cancer Treatment Research Foundation, a not-for-profit cancer research organization, Cartilage Technologies, a shark cartilage manufacturer, and Cancer Treatment Centers of America (CTCA), a national healthcare management company which specializes in comprehensive The study followed 60 people with advanced cancer who were prescribed a daily oral dose of shark cartilage as their only form of anti-cancer treatment. The study was designed to treat patients for a minimum of 12 weeks. None of the patients achieved a complete or partial response to the shark cartilage treatment. Ten patients had stable disease (no progression of their cancer) for 12 weeks or more. Only two patients had an improvement in quality of life as measured by a quantitative scale. "In conclusion," the report states, "shark cartilage was inactive in patients with advanced stages of cancer, specifically in breast, colon, lung, and prostate cancer." "This is the largest study every conducted to determine whether or not shark cartilage is an effective treatment modality for cancer," says Denis Miller, MD, principal investigator and former medical director of Cancer Treatment Research Foundation. "Until now, supporting preclinical studies were scanty and reports of trials in humans were anecdotal, uncontrolled, and outside of the peer-review mechanism."
|